“The IDEAL Trial - a Study Protocol for a Phase III Randomized, Double-Blinded Clinical Trial Assessing the Ultra-Short Antibiotic Prophylaxis of Isoniazid and Rifapentine in Non-Immunosuppressed Patients With Newly Diagnosed Latent Tuberculosis”. Principles and Practice of Clinical Research, vol. 6, no. 1, May 2020, pp. 9-14, https://journal.ppcr.org/index.php/ppcrjournal/article/view/96.